The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
On June 2, 2023, CMS issued a memo via HPMS reminding plan sponsors of requirements
related to the pharmacy price concessions provisions in the May 9, 2022 final rule (CMS-4192-
F).
Don't miss out on your chance to comment! Health care expert Fred Goldstein sits down with Ellen Whipple, BS Pharm, PharmD, to discuss the AMCP Format revision focused on digital therapeutics, health disparities, real-world evidence, PIE Deck guidance, and streamlining dossier development.
Health care expert Fred Goldstein, host of the AMCP Podcast Series — Listen Up! sits down with Melissa Andel, Principal and Founder of CommonHealth Solutions to take a closer look at the recent action on Capitol Hill surrounding pharmacy benefit manager reform.
On January 31, 2020, HHS declared a public health emergency (Declaration) pursuant to the
Public Readiness and Emergency Preparedness Act (PREP Act), in response to the COVID–
19 outbreak.
The Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug
Enforcement Administration (DEA) are issuing this temporary rule to extend certain exceptions
granted to existing DEA regulations in March 2020 because of the COVID-19 Public Health
Emergency (COVID-19 PHE).
AMCP's volunteers are vital players in propelling our mission forward. In this installment of the AMCP Volunteer Spotlight, we are featuring Matt Moen, PharmD, MBA, AMCP Membership Committee member.